Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Amiodarone- and lithium-related thyroid dysfunction

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Amiodarone-associated thyrotoxicosis can precipitate arrhythmia or heart failure with few classic symptoms; unstable cardiovascular disease needs monitored acute care and same-day cardiology-endocrinology decisions. Lithium toxicity with neurological change, vomiting, acute kidney injury or marked tremor is a separate emergency requiring an urgent lithium level and toxicology pathway.

Overview

Detect and phenotype thyroid dysfunction caused by amiodarone or lithium, coordinate essential-drug decisions and treat hypo- or hyperthyroidism without causing cardiac or psychiatric harm.

Amiodarone contains a large iodine load and directly changes thyroid hormone metabolism. Euthyroid patients may show transient TSH elevation and higher free T4 with lower free T3 after initiation. Persistent TSH elevation with low free T4 supports hypothyroidism; suppressed TSH with raised hormone indicates thyrotoxicosis, but phenotyping its synthesis-driven and destructive components can be difficult.

Lithium concentrates in the thyroid and impairs hormone release, promoting goitre and hypothyroidism in susceptible patients. Autoimmunity may coexist, and destructive or Graves-like hyperthyroidism is possible. Treatment should protect mental-health stability: thyroid dysfunction is often managed alongside continued lithium, while the psychiatry team reassesses lithium only when the overall benefit-risk demands it.

Both drugs have effects beyond the thyroid. Amiodarone surveillance also includes liver, lung, eye, neurological and cardiac toxicity; lithium care includes plasma concentration, renal function, calcium, hydration and interactions. A thyroid result must therefore trigger a whole-medicine safety review rather than a narrow prescription.

Aetiology

01

Amiodarone exposure

A large iodine load and direct effects on thyroid hormone metabolism can produce hypothyroidism, synthesis-driven thyrotoxicosis or destructive hormone release.

02

Lithium exposure

Lithium concentrates within the thyroid and impairs hormone release, promoting goitre and hypothyroidism, while autoimmune or destructive hyperthyroid patterns may also occur.

Pathophysiology

  1. 1
    Thyroid handling is altered

    Amiodarone changes iodine availability and peripheral hormone metabolism, while lithium interferes with glandular hormone release and can enlarge susceptible thyroid tissue.

  2. 2
    Compensation may fail

    Early biochemical changes can be physiological adaptations, but persistent disruption may exceed thyroid reserve and produce genuine low or high circulating hormone.

  3. 3
    Systemic illness amplifies harm

    Resulting thyroid dysfunction interacts with arrhythmia, heart failure, mood instability, renal function and medicine toxicity, making interpretation and drug decisions multidisciplinary.

Clinical features and red flags

Amiodarone hypothyroidism

Persistent raised TSH with low free T4, cold intolerance, constipation or bradycardia supports overt hypothyroidism. Clinical recognition may be masked by cardiac disease and beta-blockers.

Type 1 AITRed flag

Underlying nodular goitre or Graves' disease, thyroid vascularity and positive relevant antibodies can support iodine-driven increased synthesis. The distinction is probabilistic and may not be clean.

Type 2 AITRed flag

A previously normal gland, low vascularity and destructive release favour type 2 amiodarone-induced thyrotoxicosis. Inflammatory markers alone are insufficiently specific to make the diagnosis.

Lithium hypothyroidism

Progressive TSH elevation, low free T4, goitre or thyroid antibodies during lithium therapy suggests impaired output. Fatigue or low mood should not be assumed to represent psychiatric relapse.

Systemic medicine toxicityRed flag

Dyspnoea, cough, jaundice, visual change or neuropathy on amiodarone, and diarrhoea, vomiting, coarse tremor, ataxia, confusion or renal decline on lithium, require broader urgent toxicity assessment.

Investigations

  1. 01
    Serial TSH, free T4 and free T3First step
    Why
    Confirm persistent dysfunction and characterise its biochemical direction and severity.
    Interpretation and limitations
    Compare with the pre-drug baseline and timing. Amiodarone often raises free T4 and lowers free T3 without thyrotoxicosis; suppressed TSH plus rising free hormone and cardiac deterioration is more concerning.
  2. 02
    Thyroid antibodies
    Why
    Identify autoimmune susceptibility and support Graves' or autoimmune hypothyroid mechanisms.
    Interpretation and limitations
    TSH-receptor antibody positivity supports Graves' activity; TPO antibodies predict hypothyroid risk but do not alone prove current hormone failure. Negative antibodies do not exclude nodular type 1 AIT.
  3. 03
    Thyroid ultrasound with colour Doppler
    Why
    Assess goitre, nodules and vascularity when amiodarone thyrotoxicosis needs phenotyping.
    Interpretation and limitations
    Increased flow supports synthesis-driven disease and low flow supports destruction, but overlap and operator dependence mean results must be integrated with history and biochemistry.
  4. 04
    ECG, observations and cardiac assessment
    Why

Differential diagnosis

01

Expected amiodarone adaptation

Transient TSH elevation with altered free-hormone balance soon after starting amiodarone may reflect medicine physiology rather than established thyroid disease.

02

Autoimmune thyroid disease

Thyroid antibodies, diffuse gland features or eye disease can indicate coincident Hashimoto or Graves disease rather than a purely toxic drug effect.

03

Non-thyroidal illness

Acute systemic illness can distort TSH and free hormones; clinical context and repeat testing help avoid attributing every abnormal profile to amiodarone or lithium.

Management

01Amiodarone hypothyroidismReplace while protecting rhythm controlFirst stepPersistent overt biochemical hypothyroidism during or after amiodarone exposure.+
  1. 1Confirm persistence, symptoms and baseline pattern; check adrenal risk if severe central features are possible and review all amiodarone toxicities.
  2. 2Discuss amiodarone indication with cardiology. It can often continue while levothyroxine is introduced cautiously, especially in ischaemic or arrhythmic heart disease.
  3. 3Titrate against TSH and free T4 with clinical cardiac review, accepting that amiodarone alters peripheral conversion and that abrupt over-replacement may provoke arrhythmia.
02Amiodarone thyrotoxicosisPhenotype and treat in parallelSuppressed TSH with raised free hormone and compatible change during amiodarone exposure.+
  1. 1

Complications

01

Cardiac decompensation

Thyrotoxicosis can worsen tachyarrhythmia or heart failure, while hypothyroidism may aggravate bradycardia and impaired cardiac function in already vulnerable patients.

02

Psychiatric destabilisation

Unrecognised thyroid dysfunction or abrupt alteration of effective lithium treatment can worsen mood stability, so endocrine and psychiatric decisions require coordination.

03

Multiorgan medicine toxicity

A thyroid abnormality may coexist with amiodarone liver, lung, eye or neurological toxicity, or lithium accumulation, renal impairment and calcium disturbance.

Monitoring and follow-up

  • For amiodarone, record baseline thyroid tests, repeat at six-month intervals during treatment and continue for several months after cessation, increasing frequency when abnormal.
  • Track free hormones as well as TSH during AIT treatment, together with heart rate, rhythm, heart failure findings and adverse effects of thionamide or glucocorticoid therapy.
  • For lithium, follow the NICE schedule for plasma lithium, eGFR, urea/electrolytes, calcium and thyroid function, with extra testing after illness, interacting drugs or renal change.
  • After starting levothyroxine, reassess symptoms and tests after an appropriate steady-state interval; avoid rapid escalation solely because fatigue persists from another cause.
  • Document which specialty owns amiodarone or lithium decisions, the toxicity safety-net, and the follow-up plan after any hospital admission or medicine interruption.

Special situations

Amiodarone rewrites normal tests

Inhibition of deiodination can leave free T4 high-normal and free T3 low-normal in a euthyroid patient. Baseline and trend prevent treatment of an expected pharmacological pattern.

AIT typing is not binary

Nodular synthesis and destructive injury can coexist. When cardiac risk is high, specialists may treat both components while refining the phenotype from response and imaging.

Withdrawal has delayed biology

Amiodarone persists in tissues, so stopping it does not rapidly remove iodine or antiarrhythmic effects. The decision must be about overall cardiac benefit, not an expectation of immediate thyroid recovery.

Lithium need not lose

Concurrent levothyroxine often manages lithium-associated hypothyroidism successfully. Abruptly removing an effective mood stabiliser can exchange a treatable endocrine problem for serious psychiatric relapse.

Check calcium beside TSH

Long-term lithium surveillance includes calcium because hyperparathyroidism can mimic or compound fatigue, mood change, constipation and renal symptoms attributed to thyroid disease.

Common pitfalls

  1. 01

    Diagnosing amiodarone thyrotoxicosis from a mildly high free T4 without considering TSH, free T3, timing and baseline.

  2. 02

    Excluding dangerous AIT because there is no striking tremor or tachycardia in a heavily treated cardiac patient.

  3. 03

    Stopping amiodarone without cardiology input or stopping lithium without a psychiatric continuity plan.

  4. 04

    Treating destructive type 2 AIT with thionamide alone and waiting through cardiovascular deterioration.

  5. 05

    Attributing new confusion or coarse tremor solely to thyroid dysfunction without checking lithium concentration and renal function.

  6. 06

    Ending thyroid surveillance immediately when amiodarone is discontinued despite its prolonged persistence.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Amiodarone monitoring interval

A patient with normal baseline thyroid tests starts long-term amiodarone. Which monitoring plan best reflects current MHRA safety advice?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • MHRA amiodarone monitoring and supervision reminderNational safety advice including baseline, six-monthly and post-discontinuation thyroid tests.
  • NICE CG185 bipolar disorder recommendationsLithium physical-health, renal, calcium and thyroid monitoring framework.
  • Priadel lithium carbonate Summary of Product CharacteristicsRegulatory information on lithium-associated thyroid, calcium, renal and neurological effects.
  • NICE NG145 thyroid disease recommendationsGeneral interpretation and treatment framework for hypo- and hyperthyroidism.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Key points

  • Check thyroid function before amiodarone, every six months during treatment and for several months after discontinuation, as MHRA advises; its long tissue half-life makes late effects biologically plausible.
  • Amiodarone can cause hypothyroidism or thyrotoxicosis. High iodine exposure and inhibition of T4-to-T3 conversion also produce predictable early laboratory changes that are not automatically disease.
  • Type 1 amiodarone-induced thyrotoxicosis reflects increased synthesis, often in Graves' or nodular thyroid disease; type 2 is destructive thyroiditis. Mixed or indeterminate forms are common in practice.
  • A normal or modest free T3 does not safely exclude amiodarone-associated thyrotoxicosis because conversion is inhibited and severe cardiac disease may blunt classical symptoms.
  • Stopping amiodarone is not a reflex endocrine decision: benefit may persist after withdrawal and arrhythmia control may be life-saving. Cardiology and endocrinology should agree the risk balance.
  • Lithium commonly causes goitre or hypothyroidism and can less commonly cause thyrotoxicosis. Hypothyroidism can often be treated with levothyroxine without withdrawing an effective mood stabiliser.
  • NICE recommends thyroid function, renal function and calcium monitoring at least every six months during long-term lithium treatment, with more frequent review when results change or risk is greater.
  • Symptoms overlap: fatigue, weight change, tremor, anxiety, bradycardia and cognitive slowing may arise from thyroid disease, the underlying cardiac/psychiatric illness or medicine toxicity. Use biochemistry and trajectory.
  • Lithium-associated hypercalcaemia or hyperparathyroidism is not thyroid dysfunction but belongs in the same safety review and can contribute to neuropsychiatric and renal symptoms.
Identify arrhythmia, ischaemia or heart failure caused or worsened by thyroid dysfunction.
Interpretation and limitations
Cardiovascular instability determines urgency and may outweigh the textbook biochemical phenotype. Amiodarone can obscure tachycardia despite severe thyrotoxicosis.
  • 05
    Lithium concentration, U&E, eGFR and calcium
    Why
    Separate thyroid symptoms from lithium toxicity and detect renal or parathyroid complications.
    Interpretation and limitations
    Interpret lithium level against dose time, hydration, acute illness and interacting medicines. Falling eGFR or hypercalcaemia needs coordinated review even when the thyroid abnormality is mild.
  • 06
    Liver profile, chest assessment and relevant imaging
    Why
    Look for concurrent amiodarone toxicity and establish whether proposed treatment is safe.
    Interpretation and limitations
    Abnormal liver tests can reflect amiodarone or antithyroid treatment; respiratory symptoms may require CT rather than relying on a normal chest radiograph, following MHRA advice.
    • Assess cardiovascular stability immediately, obtain antibodies and Doppler imaging, and involve endocrinology and cardiology rather than waiting for perfect type 1/type 2 certainty.
  • 2Use a thionamide for a synthesis-predominant pattern, glucocorticoid for a destructive pattern, or specialist combination therapy when mixed or life-threatening disease is plausible.
  • 3DefinitiveReassess biochemistry and cardiac status frequently. Consider definitive thyroidectomy at an experienced centre when medical control fails or cardiac deterioration makes prolonged thyrotoxicosis unacceptable.
    • 03Lithium dysfunctionTreat thyroid disease without destabilising moodNew abnormal TSH/free T4, goitre or thyroid symptoms during lithium treatment.+
    1. 1Repeat and classify the thyroid abnormality, check antibodies where helpful, and concurrently review lithium concentration, renal function, calcium, adherence and interacting medicines.
    2. 2For overt hypothyroidism, introduce levothyroxine and usually continue effective lithium while psychiatry participates; subclinical disease is individualised by symptoms, TSH trajectory and risk.
    3. 3For thyrotoxicosis, establish Graves', nodular or destructive mechanism and treat accordingly. Any lithium reduction or cessation needs an explicit psychiatric relapse-prevention plan.
    Key medicines and prescribing safety4 treatments · regimens, roles and cautions+
    Treats overt amiodarone- or lithium-associated hypothyroidism while the causative medicine may continue when clinically essential.

    Levothyroxine

    Start cautiously and titrate in older adults or those with ischaemic and rhythm disease; otherwise follow BNF replacement principles and serial tests.

    Over-replacement may worsen angina or arrhythmia. Separate from absorption-interfering medicines and interpret free T4 carefully because amiodarone changes conversion.

    Inhibits new hormone synthesis in type 1 or a synthesis component of mixed amiodarone-induced thyrotoxicosis.

    Carbimazole for synthesis-predominant AIT

    High iodine exposure may require a specialist-selected regimen and close biochemical review; prescribe only with endocrinology oversight.

    Give agranulocytosis and hepatic warnings. It is ineffective as sole mechanistic therapy for purely destructive disease and response may be slow in an iodine-loaded gland.

    Reduces inflammatory destructive hormone release in type 2 or the destructive component of mixed amiodarone thyrotoxicosis.

    Prednisolone for destructive AIT

    Specialist course and taper chosen from severity, response, diabetes, infection and comorbidity; avoid an unreviewed prolonged regimen.

    Monitor glucose, infection, mental state, blood pressure, bone and adrenal suppression risk. Relapse during taper may require reassessment rather than automatic indefinite exposure.

    Preserves effective mood stabilisation while concurrent levothyroxine treats common lithium-associated hypothyroidism.

    Lithium carbonate continuation with replacement

    Maintain only the psychiatry-agreed dose and target plasma concentration; thyroid disease does not justify unsupervised dose alteration.

    Narrow therapeutic index: dehydration, NSAIDs, ACE inhibitors, angiotensin receptor blockers and some diuretics can raise levels. Monitor renal function, calcium, thyroid status and toxicity symptoms.